Piramal Pharma Share Price Today (PPLPHARMA)
TODAY IN ONE LINE
PPLPHARMA rose 2.6% on above-average volume (2.1x avg), outperforming Nifty's 1.1% move.
With a market cap of ₹23,275.14 Cr., it trades at a P/E of -73.29. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Piramal Pharma flags
Key strengths and potential risks.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 0.1% YoY
What changed recently?
Recent events, corporate actions, and announcements.
Piramal Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Piramal Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Piramal Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Piramal Pharma Limited — derived from the live tape, not yesterday's close.
Piramal Pharma Limited last traded at ₹179.42 with an intraday range of ₹172.1–₹181.6 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹179.42| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 202.31 | +22.89 | +12.76% |
| R3 | 192.81 | +13.39 | +7.46% |
| R2 | 187.21 | +7.79 | +4.34% |
| R1 | 183.31 | +3.89 | +2.17% |
| PIVOT | 177.71 | -1.71 | -0.95% |
| CURRENT | 179.42 | — | — |
| S1 | 173.81 | -5.61 | -3.12% |
| S2 | 168.21 | -11.21 | -6.25% |
| S3 | 164.31 | -15.11 | -8.42% |
| S4 | 154.81 | -24.61 | -13.71% |
PPLPHARMA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹172.66–₹177.09
Trading Above opening range, showing Bullishness
Piramal Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Piramal Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Piramal Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹23,275.14 Cr. and reported EPS of ₹-2.45.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 9,151 | 8,869 ▼ 3.1% |
| Sales Growth YoY %Derived | 11.99% | -3.08% |
| Other Income | 135 | 213 ▲ 58.2% |
| Total Income | 9,286 | 9,082 ▼ 2.2% |
| 3,232 | 3,239 ▲ 0.2% | |
| Gross ProfitDerived | 5,920 | 5,631 ▼ 4.9% |
| Gross Margin %Derived | 64.69% | 63.49% |
| 4,475 | 4,709 ▲ 5.2% | |
| EBITDA (Operating Profit)Derived | 1,445 | 922 ▼ 36.2% |
| OPM %Derived | 15.79% | 10.39% |
| 1,238 | 976 ▼ 21.2% | |
| Profit Before Tax (PBT) | 342 | -233 ▼ 168.3% |
| 324 | 150 ▼ 53.7% | |
| Effective Tax %Derived | 94.67% | -64.25% |
| Total Profit for Period | 91 | -326 ▼ 457.7% |
| Net Profit (Owner's PAT)Derived | 91 | -326 ▼ 457.7% |
| Net Profit Margin %Derived | 1.00% | -3.68% |
| PAT Growth YoY %Derived | 411.39% | -457.66% |
| Earnings Per Share (EPS ₹) | 0.69 | -2.45 ▼ 455.1% |
| Diluted Shares Outstanding (Cr) | 133 | 133 ▲ 0.3% |
| Share of Profit from Associates/JVs | 73 | 57 ▼ 21.6% |
| Other Comprehensive Income (Net of Tax) | 80 | 338 ▲ 323.9% |
| Total Expenses (incl. D&A & Interest) | 8,944 | 9,316 ▲ 4.2% |
| Material Cost % of RevenueDerived | 22.46% | 22.50% |
| Employee Cost % of RevenueDerived | 25.21% | 27.24% |
| Other Cost % of RevenueDerived | 23.68% | 25.85% |
| Interest Coverage (x)Derived | 1.49x | 0.27x |
| Period | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 7,082 | 8,171 ▲ 15.4% | 9,151 ▲ 12.0% | 8,869 ▼ 3.1% | |
| Sales Growth YoY %Derived | — | 15.39% | 11.99% | -3.08% | |
| Other Income | 225 | 175 ▼ 22.1% | 135 ▼ 23.1% | 213 ▲ 58.2% | |
| Total Income | 7,307 | 8,347 ▲ 14.2% | 9,286 ▲ 11.3% | 9,082 ▼ 2.2% | |
2,703 | 2,954 ▲ 9.3% | 3,232 ▲ 9.4% | 3,239 ▲ 0.2% | ||
| Gross ProfitDerived | 4,378 | 5,217 ▲ 19.2% | 5,920 ▲ 13.5% | 5,631 ▼ 4.9% | |
| Gross Margin %Derived | 61.83% | 63.85% | 64.69% | 63.49% | |
3,750 | 4,021 ▲ 7.2% | 4,475 ▲ 11.3% | 4,709 ▲ 5.2% | ||
| EBITDA (Operating Profit)Derived | 628 | 1,196 ▲ 90.4% | 1,445 ▲ 20.8% | 922 ▼ 36.2% | |
| OPM %Derived | 8.87% | 14.64% | 15.79% | 10.39% | |
1,014 | 1,126 ▲ 11.1% | 1,238 ▲ 9.9% | 976 ▼ 21.2% | ||
| Profit Before Tax (PBT) | -174 | 120 ▲ 168.7% | 342 ▲ 185.2% | -233 ▼ 168.3% | |
66 | 161 ▲ 143.5% | 324 ▲ 100.4% | 150 ▼ 53.7% | ||
| Effective Tax %Derived | -38.00% | 134.78% | 94.67% | -64.25% | |
| Total Profit for Period | -186 | 18 ▲ 109.6% | 91 ▲ 411.4% | -326 ▼ 457.7% | |
| Net Profit (Owner's PAT)Derived | -186 | 18 ▲ 109.6% | 91 ▲ 411.4% | -326 ▼ 457.7% | |
| Net Profit Margin %Derived | -2.63% | 0.22% | 1.00% | -3.68% | |
| PAT Growth YoY %Derived | — | 109.56% | 411.39% | -457.66% | |
| Earnings Per Share (EPS ₹) | -1.41 | 0.13 ▲ 109.2% | 0.69 ▲ 430.8% | -2.45 ▼ 455.1% | |
| Diluted Shares Outstanding (Cr) | 132 | 132 ▼ 0.0% | 133 ▲ 0.2% | 133 ▲ 0.3% | |
| Share of Profit from Associates/JVs | 54 | 59 ▲ 9.5% | 73 ▲ 22.6% | 57 ▼ 21.6% | |
| Other Comprehensive Income (Net of Tax) | 176 | 57 ▼ 67.7% | 80 ▲ 40.7% | 338 ▲ 323.9% | |
| Total Expenses (incl. D&A & Interest) | 7,481 | 8,227 ▲ 10.0% | 8,944 ▲ 8.7% | 9,316 ▲ 4.2% | |
| Material Cost % of RevenueDerived | 23.76% | 24.19% | 22.46% | 22.50% | |
| Employee Cost % of RevenueDerived | 26.78% | 24.84% | 25.21% | 27.24% | |
| Other Cost % of RevenueDerived | 26.18% | 24.37% | 23.68% | 25.85% | |
| Interest Coverage (x)Derived | -0.14x | 1.02x | 1.49x | 0.27x |
Piramal Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Piramal Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Piramal Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Piramal Pharma Limited.
Our AI distills the core fundamental drivers supporting Piramal Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Piramal Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Diversified CDMO, hospital generics, and consumer healthcare segments across 100+ countries globally.
Operating cash flow ₹889.76 Cr (9M FY2026) exceeds net losses, demonstrating strong cash conversion quality.
Institutional ownership 21.36% reflects meaningful investor confidence and portfolio support.
Current ratio 1.43x (current assets ₹59,530 Cr / current liabilities ₹41,597 Cr) indicates adequate short-term liquidity.
Promoter holding stable at 34.86%, ensuring aligned long-term strategic interests with management.
Key Risks.
Net margin −3.68% TTM reflects persistent unprofitability and severe operational challenges.
ROE −3.83% indicates poor shareholder value creation and capital destruction.
Latest quarterly EPS declined 25% YoY despite revenue stability, signaling earnings deterioration.
TTM revenue declined 10% YoY, indicating contraction in top-line growth momentum.
Forward P/E 36.59x suggests significant overvaluation risk relative to normalized earnings.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.20. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 0.04%.
Piramal Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Piramal Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Piramal Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Piramal Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Piramal Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Piramal Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Piramal Pharma Limited stood at 46.8% of traded volume, against a 20-day average of 37.5%.
Piramal Pharma announcements: results, concalls, ratings, M&A.
Filings Piramal Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Piramal Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 148 documents below.
General Updates
Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility located at Sellersville (USA) facility
Copy of Newspaper Publication
Newspaper Advertisement for dispatch of notice of the 6th Annual General Meeting ( AGM ) and E-Voting Information
Updates
Business Responsibility & Sustainability Report for the financial year 2025-26
Shareholders meeting
Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025 26
Disclosure under SEBI Takeover Regulations
Ajay G. Piramal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Investor decks & rating reports.
Piramal Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Piramal Pharma has declared, sequenced by announce and record date.
Piramal Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Piramal Pharma Limited: business, sector, key facts.
What Piramal Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Piramal Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: PPLPHARMA, BSE: 543635.
Piramal Pharma Limited (PPLPHARMA) is a multinational pharmaceutical company with a global reach, encompassing North America, Europe, Japan, India, and other international markets. Its core business revolves around the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products and services. This broad approach allows them to cater to a wide range of needs within the industry.
A significant portion of PPLPHARMA's operations involves contract development and manufacturing organization (CDMO) services. This segment offers a comprehensive suite of services across the entire drug lifecycle. This includes assistance with drug discovery, development, and the commercial manufacturing of both drug substances and finished products. This CDMO arm positions PPLPHARMA as a key partner for other pharmaceutical companies needing outsourced manufacturing and development capabilities.
Beyond CDMO services, PPLPHARMA maintains a robust internal portfolio of pharmaceutical products. A key area of focus is their complex hospital generics business. This division specializes in high-demand products like inhalation anesthetics, intrathecal therapies used in spasticity management, injectable pain and anesthesia medications, and other specialized generic and branded products. This segment targets the hospital and healthcare sector, providing essential medications.
In addition to its global and hospital-focused operations, PPLPHARMA also has a substantial presence in the Indian consumer healthcare market. This domestic segment offers a wide array of over-the-counter (OTC) products targeting various health needs. Their consumer healthcare portfolio includes analgesics (pain relievers), skincare products, vitamin and mineral supplements, children's wellness products, digestive aids, women's health products, and hygiene and protection items. This diversification within the Indian market allows them to tap into a broad consumer base.
In summary, PPLPHARMA's business model is built on a multifaceted approach. They function as both a CDMO providing services to other pharmaceutical companies and a direct producer and distributor of their own branded and generic pharmaceutical products across various segments, including the hospital market and the Indian consumer healthcare market. This strategic diversification minimizes reliance on any single sector and positions the company for sustained growth.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Piramal Pharma Limited (PPLPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Piramal Pharma Limited (PPLPHARMA)?
The current share price of Piramal Pharma Limited (PPLPHARMA) is ₹179.42. Today, the stock has gained by ₹4.63 (2.65%), trading in a range of ₹172.1 to ₹181.6. The stock opened at ₹175.9 with a trading volume of 67,00,414 shares.
02Is Piramal Pharma Limited stock a good investment for long-term?
Piramal Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹23,275.14 crores, P/E ratio of -73.29, ROE of -3.83%, and ROCE of 2.52%. The dividend yield stands at 0.08%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Piramal Pharma Limited stock?
The 52-week high price of Piramal Pharma Limited (PPLPHARMA) is ₹220.85, while the 52-week low is ₹132.3. Currently trading at ₹179.42, the stock is 53.2% away from its 52-week low and 18.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Piramal Pharma Limited stock at the current price?
Whether to buy Piramal Pharma Limited stock at ₹179.42 depends on multiple factors. The stock is currently trading with a P/E ratio of -73.29 and P/B ratio of 2.92. Today's performance shows a gain of 2.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Piramal Pharma Limited and when is the next dividend?
Piramal Pharma Limited offers a dividend yield of 0.08%, which means for every ₹100 invested at the current price of ₹179.42, you can expect to receive approximately ₹0.08 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Piramal Pharma Limited?
Piramal Pharma Limited's key financial metrics include: P/E Ratio: -73.29, P/B Ratio: 2.92, ROE: -3.83%, ROCE: 2.52%, Dividend Yield: 0.08%, EPS: ₹-2.45, Book Value: ₹64.78, and Debt-to-Equity: 0.70. The company's market cap stands at ₹23,275.14 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Piramal Pharma Limited stock performing today in the market?
Piramal Pharma Limited stock opened at ₹175.9 and is currently trading at ₹179.42, showing a gain of ₹4.63 (2.65%). The intraday high is ₹181.6 and low is ₹172.1. The trading volume stands at 67,00,414 shares, indicating strong market participation today.
08What is the P/E ratio of Piramal Pharma Limited and what does it indicate?
Piramal Pharma Limited has a Price-to-Earnings (P/E) ratio of -73.29, which means investors are willing to pay ₹-73.29 for every ₹1 of earnings. With an EPS of ₹-2.45, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Piramal Pharma Limited (PPLPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.